Every round on record, with the sources behind each and the investors on them.
A commercial-stage radiopharmaceutical company advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes
northstarnm.comLinkedInBeloit, Wis.OtherFounded 2006
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release names Stateline Angels among the investors supporting this financing; the other accredited investors are not identified.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source identifies Madison, WI as the dateline, not as the company's headquarters.
Publication audit: leads should be Stateline Angel Investors (https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-5-2-million-additional-funding-safe-domestic-radioisotope-production)
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $13.5M | 2013-09-17 | Hendricks Holding Company | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The release names Stateline Angels among the investors supporting this financing; the other accredited investors are not identified. | ||||
NorthStar makes commercial-scale medical radioisotopes and provides radiopharmaceutical development and manufacturing services for pharmaceutical and biotechnology companies working to diagnose and treat cancer and other serious diseases.
NorthStar is addressing the medical-isotope supply problem by producing radioisotopes at commercial scale with non-uranium, environmentally preferred technologies, including domestic Mo-99 and commercial-scale Ac-225 and Cu-67 for cancer diagnostics and therapy. Its up-to-$185 million Hercules growth facility, including $100 million upfront, is intended to expand isotope production and integrated cGMP drug-manufacturing capacity as pharmaceutical demand grows.
Checked against 10 sources on Sep 29
| Series D+ Series D preferred stock financing [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $5.2M | 2012-09-05 | Rockford, Illinois | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source identifies Madison, WI as the dateline, not as the company's headquarters. Publication audit: leads should be Stateline Angel Investors (https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-5-2-million-additional-funding-safe-domestic-radioisotope-production) [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: northstarnm.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Investment | $6 million | 2010 | not stated | |
Also named as backers in company research: Stateline Angel Investors, Accredited local investors, U.S. Department of Energy, National Nuclear Security Administration (NNSA), Hercules Capital, Inc.